Citrullinemia Type II: Navigating the Genetic Pathways to Diagnosis and Management

In the labyrinth of rare metabolic disorders, Citrullinemia Type II (CTLN2) stands out due to its intricate genetic underpinnings and atypical clinical presentations. This condition, characterized by a deficiency in the urea cycle, can manifest in adulthood with symptoms that might not immediately suggest a metabolic disorder. One of the most striking presentations of CTLN2 is severe hypertriglyceridemia, a condition more commonly associated with dietary and lifestyle factors. This article explores how genetic testing can serve as a crucial tool in diagnosing and managing CTLN2, offering insights into the genetic landscape of this rare condition.

Understanding Citrullinemia Type II

Citrullinemia Type II is an autosomal recessive disorder caused by mutations in the SLC25A13 gene. This gene encodes the citrin protein, which is involved in the transport of aspartate and glutamate across the mitochondrial membrane, crucial for the urea cycle and energy production pathways. In the absence of functional citrin, ammonia and other toxic substances accumulate in the blood, leading to a spectrum of symptoms ranging from neurological disturbances to liver dysfunction.

While CTLN2 is predominantly recognized as a pediatric condition, its adult-onset form presents unique challenges. Adults may experience episodes of confusion, lethargy, and even coma, often triggered by stress, alcohol consumption, or fasting. The presence of severe hypertriglyceridemia can further obscure the diagnosis, as it is not a typical feature of urea cycle disorders.

The Role of Genetic Testing in Diagnosis

Identifying Genetic Mutations

Genetic testing plays a pivotal role in confirming a diagnosis of CTLN2. By identifying mutations in the SLC25A13 gene, clinicians can differentiate CTLN2 from other metabolic disorders with overlapping symptoms. This is especially critical in cases of adult-onset CTLN2, where the clinical presentation may not immediately suggest a urea cycle disorder. Genetic testing provides a definitive diagnosis, allowing for targeted interventions and management strategies.

Guiding Family Planning and Genetic Counseling

For individuals diagnosed with CTLN2, genetic testing is not only a tool for personal diagnosis but also an essential component of family planning. As an autosomal recessive disorder, CTLN2 requires both parents to carry a copy of the mutated gene for their child to be affected. Genetic counseling can help families understand their risk and make informed decisions about future pregnancies. Testing can also identify carriers within the family, offering insights into potential health implications and guiding preventive measures.

Informing Dietary and Lifestyle Modifications

Once a genetic diagnosis of CTLN2 is established, dietary management becomes a cornerstone of treatment. Genetic testing results can inform personalized dietary plans aimed at reducing ammonia levels and managing hypertriglyceridemia. Typically, a low-protein, high-calorie diet supplemented with specific amino acids and vitamins is recommended. Understanding the genetic basis of the disorder allows for a more tailored approach, optimizing dietary interventions to suit individual metabolic needs.

Conclusion: The Future of Genetic Testing in CTLN2

As our understanding of genetic disorders continues to evolve, the role of genetic testing in diagnosing and managing conditions like Citrullinemia Type II becomes increasingly significant. By providing a definitive diagnosis, guiding family planning, and informing tailored treatment strategies, genetic testing empowers patients and clinicians alike. As research advances, we can anticipate even more precise genetic tools that will enhance our ability to diagnose and manage rare metabolic disorders, ultimately improving patient outcomes and quality of life.

For further reading and detailed insights into the management of adult-onset CTLN2, refer to the comprehensive study available at PMC12971039.

About The Expert Reviewer

Dr. Brandon Colby MD is a US physician specializing in the personalized prevention of disease through the use of genomic technologies. He’s an expert in genetic testing, genetic analysis, and precision medicine. Dr. Colby is also the Founder of  and the author of ⁠Outsmart Your Genes.

Dr. Colby holds an MD from the Mount Sinai School of Medicine, an MBA from Stanford University’s Graduate School of Business, and a degree in Genetics with Honors from the University of Michigan. He is an Affiliate Specialist of the American College of Medical Genetics and Genomics (⁠ACMG), an Associate of the American College of Preventive Medicine (⁠ACPM), and a member of the National Society of Genetic Counselors (NSGC)